HopeStage
Back to all studies
CompletedNCT06391593

ALTO-203 safety study for adults with major depression

About this titleRead the official source — NCT06391593
Medication studyAges 25–64United States
The study in practice

Understand this study

Who was this study for?

This study was for people with depression. Listed age limits: 25 years to 64 years. Other eligibility criteria applied.

Listed locations
Tucson and 14 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: March 25, 2024
Recruitment status
Completed
Enrollment listed in the registry
69
Sponsor
Alto Neuroscience
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 25 Years to 64 Years
Official registry ID
NCT06391593
Official title
Show the full official title

Double-Blind, Single and Multiple Dose Study to Determine Pharmacodynamic Markers, Pharmacokinetic Parameters, and Safety of ALTO-203 in Patients With Major Depressive Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Tucson · Oceanside · Torrance

12 more locations
  • Clermont
  • Orlando
  • Atlanta
  • Pikesville
  • Las Vegas
  • Marlton
  • Princeton
  • Westlake
  • Austin
  • Houston
  • Clinton
  • Bellevue

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Alto Neuroscience.

Did this study involve medication?

Yes. The study involved medication, including ALTO-203 25 μg, ALTO-203 75 μg and Placebo.

Who was this study for?

This study was for people with depression. Listed age limits: 25 years to 64 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies